ExAI Report

Model Evaluation Plots

Original Patient Data

Key	Value	Key	Value
ID	77.0	N_Days	326.00000000000006
Age	18199.0	Bilirubin	6.6
Cholesterol	244.00000000000003	Albumin	3.41
Copper	199.0	Alk_Phos	1819.0
SGOT	170.5	Tryglicerides	90.99999999999999
Platelets	154.0758483033932	Prothrombin	12.1
Stage	Unknown	Status	D
Drug	Placebo	Sex	F
Ascites	N	Hepatomegaly	Y
Spiders	Y	Edema	S

Patient Data Summary

!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

LLM Detailed Summary

1. **Actual Class**: 4.0 (Fibrosis Stage) 2. **Predicted Class**: 3 (Cirrhosis Stage)

Feature Analysis: - **LIME Top Features**: - Ascites_Y <= 0.00: Importance 0.11 - Hepatomegaly_N <= 0.00: Importance -0.07 - Status_C <= 0.00: Importance 0.06 - Status_CL <= 0.00: Importance -0.05 - 0.00 < Hepatomegaly_Y <= 1.00: Importance -0.05

- **Anchor Features**: - Features: N_Days <= 0.25, Platelets <= 0.30, Hepatomegaly_N <= 0.00, Albumin <= 0.60, Copper > 0.18 - Precision: 0.9126

Model Interpretation: The model's predicted class of Stage 3 (Cirrhosis) is classified as the most likely stage based on the input features. The top LIME features indicate that Ascites_Y (absence of ascites) and Hepatomegaly_N (absence of hepatomegaly) have a significant positive impact on the predicted class, while Status_C (cirrhosis diagnosis status) has a moderate negative impact.

On the other hand, features such as N_Days (number of days between symptom onset and liver biopsy), Platelets (low platelet count), Hepatomegaly_N, Albumin (low albumin level), and Copper (elevated copper levels) are negatively impacting on predicted class.

The clinical relevance of this model lies in its ability to accurately predict liver disease stages using a combination of clinical and laboratory features. The identified key features highlight the importance of considering non-invasive diagnostic markers such as ascites, hepatomegaly, and platelet count in assessing liver function and guiding treatment decisions.

Conclusion: Based on the predicted class, we can conclude that our patient is likely to have cirrhosis stage 3. However, given a relatively high precision of 0.9126, this result should be confirmed by further medical evaluation or diagnostic tests such as imaging studies or liver biopsy. Next steps include referral to hepatology specialist for further assessment and management plan development.

Please note that, in real-world clinical scenarios, the accuracy of AI-based predictions may need to be verified through multiple testing procedures and validation methods.